8-K
filed June 18, 2026, 8:21 AM ET
ticker BCYC
CIK 0001761612
other
confidence high
sentiment neutral
materiality 0.10
Bicycle Therapeutics shareholders approve all proposals at 2026 AGM
BICYCLE THERAPEUTICS PLC
- 98.64% of shares represented; all 9 proposals passed with large majorities.
- Felix Baker re-elected with 46.2M for vs 3.4M against; Hervé Hoppenot re-elected with 49.3M for.
- Advisory vote on executive compensation passed: 48.7M for, 0.8M against.
- Ratification of PwC as auditor for FY2026 passed: 49.4M for, 0.2M against.
- Directors' remuneration policy approved: 48.2M for, 1.3M against.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BICYCLE THERAPEUTICS PLC shareholders approved To re-elect as a director Felix Baker at the 2026-06-17 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-17
Exact text from the filing
Proposal 1 – To re-elect as a director Felix Baker For Against Vote Withheld/Abstain 46,171,302 3,364,113 161,493
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BICYCLE THERAPEUTICS PLC shareholders approved To approve the directors' remuneration policy at the 2026-06-17 meeting.
- Outcome
- passed
- Meeting
- 2026-06-17
Exact text from the filing
Proposal 9 – To approve the directors’ remuneration policy, which policy is set forth in the Company’s definitive proxy statement, and which will take effect immediately after the end of the AGM For Against Vote Withheld/Abstain 48,238,031 1,293,722 165,155
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BICYCLE THERAPEUTICS PLC shareholders approved To approve, on an advisory basis, the compensation of the Company's named executive officers at the 2026-06-17 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-17
Exact text from the filing
Proposal 3 – To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement For Against Vote Withheld/Abstain 48,748,743 785,032 163,133
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BICYCLE THERAPEUTICS PLC shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-17 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-17
Exact text from the filing
Proposal 4 – To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company’s independent registered public accounting firm for the year ending December 31, 2026 For Against Vote Withheld/Abstain 49,445,128 232,627 19,153
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BICYCLE THERAPEUTICS PLC shareholders approved To re-appoint PricewaterhouseCoopers LLP as the Company's U.K. statutory auditors to hold office until the conclusion of the next annual general meeting at the 2026-06-17 meeting.
- Outcome
- passed
- Meeting
- 2026-06-17
Exact text from the filing
Proposal 5 – To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company’s U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders For Against Vote Withheld/Abstain 49,441,337 235,008 20,563
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BICYCLE THERAPEUTICS PLC shareholders approved To receive and adopt the Company's U.K. statutory annual accounts and reports for the year ended December 31, 2025 at the 2026-06-17 meeting.
- Outcome
- passed
- Meeting
- 2026-06-17
Exact text from the filing
Proposal 7 – To receive and adopt the Company’s U.K. statutory annual accounts and reports for the year ended December 31, 2025. For Against Vote Withheld/Abstain 49,138,590 553,781 4,537
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BICYCLE THERAPEUTICS PLC shareholders approved To approve the directors' remuneration report for the year ended December 31, 2025 (excluding the remuneration policy) at the 2026-06-17 meeting.
- Outcome
- passed
- Meeting
- 2026-06-17
Exact text from the filing
Proposal 8 – To approve the directors’ remuneration report for the year ended December 31, 2025, which report is set forth in the Company’s definitive proxy statement (excluding the directors’ remuneration policy) For Against Vote Withheld/Abstain 48,741,517 792,394 162,997
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BICYCLE THERAPEUTICS PLC shareholders approved To authorize the Audit Committee to determine the Company's U.K. statutory auditors' remuneration for the year ending December 31, 2026 at the 2026-06-17 meeting.
- Outcome
- passed
- Meeting
- 2026-06-17
Exact text from the filing
Proposal 6 – To authorize the Audit Committee of the Company’s Board of Directors to determine the Company’s U.K. statutory auditors’ remuneration for the year ending December 31, 2026 For Against Vote Withheld/Abstain 49,493,240 47,269 156,399
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BICYCLE THERAPEUTICS PLC shareholders approved To re-elect as a director Hervé Hoppenot at the 2026-06-17 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-17
Exact text from the filing
Proposal 2 – To re-elect as a director Hervé Hoppenot For Against Vote Withheld/Abstain 49,284,459 250,669 161,780
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.